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Abstract 
The objective of the study was to use CD146 mRNA to predict the evolution of patients with non-metastatic 
clear cell renal cell carcinoma (M0 ccRCC) towards metastatic disease, and to use soluble CD146 (sCD146) to 
anticipate relapses on reference treatments by sunitinib or bevacizumab in patients with metastatic ccRCC 
(M1). 
Methods: A retrospective cohort of M0 patients was used to determine the prognostic role of intra-tumor 
CD146 mRNA. Prospective multi-center trials were used to define plasmatic sCD146 as a predictive marker of 
sunitinib or bevacizumab efficacy for M1 patients.  
Results: High tumor levels of CD146 mRNA were linked to shorter disease-free survival (DFS) and overall 
survival (OS). ccRCC patients from prospective cohorts with plasmatic sCD146 variation <120% following the 
first cycle of sunitinib treatment had a longer progression-free survival (PFS) and OS. The plasmatic sCD146 
variation did not correlate with PFS or OS for the bevacizumab-based treatment. In vitro, resistant cells to 
sunitinib expressed high levels of CD146 mRNA and protein in comparison to sensitive cells. Moreover, 
recombinant CD146 protected cells from the sunitinib-dependent decrease of cell viability. 
Conclusion: CD146/sCD146 produced by tumor cells is a relevant biological marker of ccRCC 
aggressiveness and relapse on sunitinib treatment. 
Key words: sCD146, clear cell renal cell carcinoma, sunitinib, predictive marker, plasma 
Introduction 
Metastatic clear cell renal cell carcinomas 
(ccRCC) are highly angiogenic tumors bearing a 
mutation, deletion or methylation in the VHL gene. 
Inactivation of VHL leads to over-expression of 
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VEGF. Therefore, anti-angiogenic therapies targeting 
the VEGF/VEGFR pathway represent a paradigm for 
the treatment of ccRCC. Bevacizumab in combination 
with interferon alpha (IFN) was the first 
anti-angiogenic to be used [1] but sunitinib, a multi 
kinase inhibitor (TKI) targeting the VEGF, PDGF, 
CSF1 receptors, c-KIT, FLT3 and RET is currently the 
treatment of reference in the first-line [2]. However, 
patients ineluctably relapse. At progression on 
sunitinib, patients receive other TKI such as axitinib 
[3], pazopanib [4, 5], cabozantinib [6], inhibitors of 
immune checkpoints such as nivolumab [7] or mTOR 
inhibitors [7]. The efficacy of sunitinib is very 
heterogeneous. Some patients are refractory and die 
rapidly, most of them show a transient response and a 
minority of patients are responders for a very long 
period of time [1, 2]. These results are probably linked 
to the huge heterogeneity of ccRCC [8]. The necessity 
of an early predictive marker of sunitinib efficacy 
represents a therapeutic challenge to rapidly adapt 
treatment and propose alternative treatments among 
those available.  
CD146 (or MUC-18, MCAM) was recently 
described as a new factor involved in tumor 
angiogenesis [9]. It is a membrane glycoprotein 
present on endothelial cells but is also neo-expressed 
in several tumors including lung, melanoma, 
pancreas, prostate, breast, stomach and renal tumors 
[10-12]. In prostate cancer, neo-expression results 
from hypermethylation of the CD146 promoter [13]. 
CD146 was described as a co-receptor for VEGFR2 in 
tumor angiogenesis [14, 15], suggesting a synergistic 
role of both molecules in the development of tumor 
vascularization. In addition to the membrane- 
anchored form of CD146, we identified a soluble form 
(sCD146), which is generated by the shedding of the 
membrane-associated form [16, 17]. This soluble form 
is secreted by tumors expressing CD146 and displays 
both autocrine effects on proliferation and survival of 
cancer cells, and paracrine effects on tumor 
angiogenesis [18]. These effects are mediated through 
binding of sCD146 to the p80 isoform of angiomotin 
[18]. This sCD146 receptor is expressed on endothelial 
and tumor cells [19, 20] and inhibits the YAP 
oncoprotein [21]. Plasmatic sCD146 concentrations are 
increased in several cancers [18, 22], indicating its 
major role in the development of the pathology.  
We hypothesized that relapses on sunitinib 
occurring in ccRCC may involve an increase in 
membrane CD146 and consequently an increase in 
sCD146 production. Therefore, the detection of 
increased levels of plasmatic sCD146 could represent 
an early predictive marker of sunitinib failure, 
allowing a rapid switch to a second-line treatment 
before visualization of relapse by imaging. 
Materials and Methods 
Description of the patients 
The studies were approved by the ethics 
committee at each participating Center and were in 
agreement with the International Conference on 
Harmonization of Good Clinical Practice Guideline. 
The management of non-metastatic (M0) and 
metastatic (M1) patients is summarized in Figure S1. 
M0 patients for qPCR analysis 
Primary tumor samples (tumor section) of M0 
ccRCC patients were obtained from the Rennes 
University hospital [23]. The disease-free survival 
(DFS) and overall survival (OS) were calculated from 
patient subgroups with CD146 mRNA levels that 
were less or greater than the first quartile value 
(Figure 1 and Table S1). 
Neo-adjuvant patients for qPCR analysis 
Samples (tumor section) were obtained from 
Nice, Bordeaux and Monaco Hospitals. The patients’ 
characteristics have already been described [24]. 
Patients were treated for at least two months before 
surgery (Figure 4 and Table S3). 
Patients included in clinical trials 
Eligible patients for SUVEGIL, TORAVA and 
PREINSUT trials were at least 18 years of age and had 
metastatic ccRCC confirmed by histology, with the 
presence of measurable disease according to Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.1. 
Patients had not received previous systemic therapy 
for ccRCC and were eligible for sunitinib or 
bevacizumab combined with IFN treatment in the 
first-line setting. Patients were ineligible if they had 
symptomatic or uncontrolled brain metastases, an 
estimated lifetime less than three months, 
uncontrolled hypertension or clinically significant 
cardiovascular events (heart failure, prolongation of 
the QT interval), or a history of another primary 
cancer. All patients gave written informed consent 
(Table 1, Figures 2 and 3). 
Clinical trial design (SUVEGIL and TORAVA trial) 
The prospective cohort includes patients from 
the SUVEGIL and TORAVA trials. 
The SUVEGIL trial (clinicaltrial.gov, NCT00943 
839) was a multi-center prospective single-arm study. 
The goal of the trial was to determine whether a link 
exists between the effectiveness of therapy with 
sunitinib malate and development of blood 
biomarkers in patients with ccRCC. 24 patients 
received oral sunitinib (50 mg/day) once daily for 
four weeks (on days 1 to 28), followed by two weeks 
without treatment. Courses were repeated every 6 
 Theranostics 2018, Vol. 8, Issue 9 
 
 
http://www.thno.org 
2449 
weeks in the absence of disease progression or 
unacceptable toxicity.  
The TORAVA trial (clinicaltrial.gov, NCT006 
19268) was a randomized prospective study. Patient 
characteristics and results have been previously 
described [25]. Briefly, patients aged 18 years or older 
with untreated metastatic ccRCC were randomly 
assigned (2:1:1). 34 patients received the combination 
of bevacizumab (10 mg/kg iv every 2 weeks) and 
temsirolimus (25 mg iv weekly), or the combination of 
bevacizumab (10 mg/kg iv every 2 weeks) and IFN (9 
mIU iv trice per week), and 12 patients receive one of 
the standard treatments: sunitinib (50 mg/day orally 
for 4 weeks followed by 2 weeks off) [25]. The 
patients’ characteristics and pathological parameters 
are summarized in Table 1. 
Blood samples were collected during the 
inclusion visit (baseline) and at the end of the four 
weeks of sunitinib administration or two weeks of 
bevacizumab-based therapies.  
Prospective cohort of validation (PREINSUT trial) 
The PREINSUT trial (clinicaltrial.gov, NCT00 
930345) was a multi-center prospective single-arm 
study part of the PREDICT program (FP7 with France 
and UK). Sunitinib was given as first-line therapy (2 
cycles of 50 mg 4 weeks ON/2 weeks OFF) before 
cyto-reductive nephrectomy. The Primary Renal 
Tumor (PRT) response prior to surgery (decrease > 
10%), the progression-free survival (PFS) and OS were 
assessed. Plasmatic VEGF-A, SDF-1 and VEGFR-1 and 
-2 were prospectively studied by ELISA at the 
beginning and the end of each 4 week sunitinib 
treatment. Correlation between sunitinib pharmacok-
inetics at the end of the first cycle (C1D28) and 
biomarker change were assessed. Thirteen patients 
from this trial were assessed for sCD146 plasmatic 
levels (Table 1). 
Biochemical analysis 
Blood samples were centrifuged (10000 ×g for 
ten minutes) and the plasma collected and conserved 
at -80°C. Plasmatic levels of sCD146 were determined 
by ELISA using a CD146 ELISA Kit (Biocytex, 
Marseille, France).  
Cell culture 
786-0 (786) and HUVEC were purchased from 
the American Tissue Culture Collection. RCC10 cells 
were a kind gift of Dr WH Kaelin (Dana Farber 
Cancer Institute Boston, MA). 786-O cells resistant to 
sunitinib (786R) were generated in the laboratory as 
previously described [26]. Primary cells resistant to 
sunitinib were already described [27]. 
Tumor fragments were treated with collagenase 
overnight at 37°C and/or mechanically disaggregated 
with scalpels. Tumor cells were suspended in cell 
culture medium specific for renal cells (PromoCell, 
Heidelberg Germany). 
 
Table 1. Characteristics of the patients included in the clinical 
trials. (See Figures 2 and 3).  
 COHORT 
Treatment 
Prospective 
cohort 
Sunitinib 
Prospective 
cohort 
Bevacizumab 
Prospective 
cohort of 
validation 
Sunitinib 
neoadjuvant 
Trials (number of patients) SUVEGIL (24) 
TORAVA (12) 
TORAVA (34) PREINSUT (13) 
Number of patients 36 34 13 
Gender    
Female 6 (16.7%) 9 (26.5%) 3 (23.1%) 
Male  30 (83.3%) 25 (73.5%) 10 (76.9%) 
PRIMARY TUMOR   
Fuhrman grade     
1 1 (2.8%)  2 (5.9%) 0 (0%) 
2 9 (25%) 8 (23.5%) 0 (0%) 
3 17 (47.2%) 14 (41.2%) 6 (46.1%) 
4 9 (25%) 10 (29.4%) 4 (30.8%) 
X 0 (0%) 0 (0%) 3 (23.1%) 
pT    
1 8 (22.2%) 5 (14.7%) 1 (7.7%) 
2 10 (27.8%) 5 (14.7%) 1 (7.7%) 
3 16 (44.4%) 18 (52.9%) 8 (61.5%) 
X 2 (5.6%)  6 (17.6%) 3 (23.1%) 
pN     
0 15 (41.7%) 0 (0%) 4 (30.8%) 
1 5 (13.9%) 0 (0%) 2 (15.4%) 
2 1 (2.7%) 0 (0%) 1 (7.7%) 
X 15 (41.7%) 34 (100%) 6 (46.1%) 
BEGINNING OF THE 
TREATMENT 
  
Age at therapy initiation 
(yr) 
60.4 (9.7) 58.7 (11.3) 63.5 (9.8) 
Metastatic from the 
diagnosis 
18 (50%) 14 (41.2%) 8 (61.5%) 
Time from diagnosis to 
treatment 
   
< 1 yr 23 (63.8%) 20 (58.8%) 9 (69.2%) 
≥ 1 yr 13 (36.1%) 14 (41.2%) 4 (30.8%) 
Number of metastatic sites     
1 17 (47.2%) 17 (50%) 6 (46.1%) 
2 13 (36.1%) 10 (29.4%) 6 (46.1%) 
≥ 3 6 (16.7%) 7 (20.6%) 1 (7.7%) 
Risk factor (MSKCC)    
Good 10 (27.8%) 14 (41.2%) 0 (0%) 
Intermediate 10 (27.8%) 18 (52.9%) 0 (0%) 
Bad 8 (22.2%) 0 (0%) 0 (0%) 
X 8 (22.2%) 2 (5.9%) 13 (100%) 
Median followed (month) 34.5 (18.2-NR) 24 (23-NR) NA 
 
Gene expression microarray analysis 
Normalized RNA sequencing (RNA-Seq) data 
produced by The Cancer Genome Atlas (TCGA) were 
downloaded from cbioportal (www.cbioportal.org, 
TCGA Provisional; RNA-Seq V2). Different 
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parameters were available for 503 ccRCC tumor 
samples. The results published here are in whole or in 
part based upon data generated by the TCGA 
Research Network: http://cancergenome.nih.gov/ 
[28, 29]. 
Quantitative real-rime PCR (qPCR) 
experiments 
For tumor sample, total RNA was extracted with 
RNeasy FFPE Kit (QIAGEN, Hilden, Germany). For 
cells, total RNA was extracted with the RNeasy Mini 
Kit (QIAGEN, Hilden, Germany). The amount of 
RNA was evaluated with NanoDrop™ spectrophoto-
meters (ThermoFisher Scientific, Waltham, MA USA). 
One microgram of total RNA was used for reverse 
transcription, using the QuantiTect Reverse Transc-
ription kit (QIAGEN, Hilden, Germany), with a blend 
of oligo (dT) and random primers to prime 
first-strand synthesis. SYBR master mix plus 
(Eurogentec, Liege, Belgium) was used for qPCR and 
specific oligonucleotides (Sigma Aldrich), to assess 
mRNA expression for CD146 total (forward: 
GGCTAATGCCTCAGATCGATG; reverse: AATATG 
GTGTTGAATCTGTCTTG), CD146 short form 
(forward: CCACTGGCCTCAGCACTTCC; reverse: 
CTACTCACCTTTCTGGACAG) and CD146 long 
form (forward: TGGTTTGTACACCTTGCAGAGTA 
TTC; reverse: TGGGCAGCCGGTAGTTG). mRNA 
levels were normalized to a housekeeping mRNA 
coding for ribosomal protein large P0 (RPLP0; 
forward: CAGATTGGCTACCCAACTGTT; reverse: 
GGCCAGGACTCGTTTGTACC). 
Cell viability (XTT) 
5×103 cells were incubated in a 96-well plate with 
different effectors for the times indicated in the figure 
legends. Fifty microliters of sodium 3′-[1-phenyl-
aminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitr
o) benzenesulfonicacid hydrate (XTT) reagent was 
added per well. The assay was based on the cleavage 
of the yellow tetrazolium salt XTT to form an orange 
formazan dye by metabolically active cells. The 
absorbance of the formazan product, reflecting cell 
viability, was measured at 490 nm. Each assay was 
performed in quadruplicate.  
Anti-soluble CD146 antibody 
The M2J-1 mAb (AC CD146) was used to inhibit 
the effects of soluble CD146. This antibody was 
produced in our laboratory (18) and is specific for the 
soluble form of the molecule since it does not 
recognize the membrane forms. 
Cell proliferation 
Human Umbilical Vein Endothelial Cells 
(HUVEC) or 786-O/786-R cells were seeded on 
96-well plates (5.103 cells/well) and cultured in 
EGM-2 medium or renal cells culture medium, 
respectively. Cell proliferation was assessed using the 
BrdU Labeling and Detection Kit III (Roche 
Corporation) as indicated by the manufacturer. In 
experiments performed in the presence of the 
anti-soluble CD146 antibody, it was added at a final 
concentration of 1µg/mL. Experiments were 
performed at least in triplicate. 
Immunoblotting 
Cells were lyzed in buffer containing 3% SDS, 
10% glycerol and 0.825 mM Na2HPO4. 30-50 μg of 
proteins was separated on 10% SDS-PAGE, 
transferred onto a PVDF membrane (Immobilon, 
Millipore) and then exposed to the appropriate 
antibodies. Proteins were visualized with the ECL 
system using horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse secondary antibodies. 
Flow cytometry 
After stimulation, cells were washed with PBS 
and stained with CD146-PE antibody (Biocytex, 
Marseille, France) according to the manufacturer’s 
procedure. Fluorescence was measured using the FL2 
of a fluorescence-activated cell sorter apparatus 
(FACS-Calibur cytometer). 
Statistical analysis  
For in vitro analysis 
Results are expressed as the mean ± the standard 
error (SEM). Statistical significance and p values were 
determined by the two-tailed Student’s t-test. One 
way ANOVA was used for statistical comparisons. 
Data were analyzed with Prism 5.0b (GraphPad 
Software) by one-way ANOVA with Bonferroni post 
hoc. 
For patient analysis 
DFS was defined as the time from surgery to the 
appearance of metastasis. PFS was defined as the time 
between surgery and subsequent blood sampling and 
progression, or death from any cause, censoring live 
patients and progression free at last follow-up. OS 
was defined as the time from blood sample collection 
to the date of death from any cause, censoring those 
alive at last follow-up. The Kaplan Meier method was 
used to produce survival curves and analyses of 
censored data were performed using Cox models.  
Smoothing splines curves for hazard ratio were 
used to determine cut-offs for censored data for 
sunitinib or bevacizumab treatments. All analyses 
were performed using R software, version 3.2.2 
(Vienna, Austria, https://www.r-project.org/). 
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Results 
The level of CD146 mRNA was predictive of 
DFS and OS in non-metastatic ccRCC patients  
Despite the major role of CD146 in the 
aggressiveness of several tumors, our goal was to 
correlate CD146 to the disease progression of M0 
patients. These patients have variable outcomes and 
relevant biological markers may improve their 
surveillance. We showed by IHC that CD146 is 
expressed by ccRCC cells (Figure S2). Analysis of 
online available data showed that tumors expressing 
the highest levels of CD146 mRNA are ccRCC (Figure 
S3). Moreover, high levels of CD146 mRNA in the 
tumors of M0 patients (first quartile cut-off, n=25/38) 
correlated with a shorter DFS (82 months versus not 
reached, p = 0.0222) and OS (122 months versus not 
reached, p = 0.0244; Figure 1 and Table S1). 
An increase in the plasmatic level of sCD146 
was predictive of PFS and OS in metastatic 
ccRCC patients treated with sunitinib  
The purpose of our study was to correlate 
sCD146 with survival in a prospective cohort of 
patients treated with sunitinib (SUVEGIL + TORAVA 
trials). Their median PFS was 15.4 months and their 
median OS was 24.6 months (Figures S4A and B). 
sCD146 levels were highly variable and did not 
correlate with outcome. Hence, we analyzed sCD146 
in patients that had an objective response (category 1), 
a stable (category 2) or a progressive disease (category 
3) according to RECIST 1.1 after the first cycle of 
treatment with sunitinib. Patients of categories 1 and 2 
had decreased or stable levels of plasmatic sCD146, 
whereas patients of category 3 presented with an 
increase in sCD146 levels (median value of 
up-regulation ≥ 120%; see Materials and Methods for 
the definition of this threshold). According to the 
definition of this threshold, the modulation of sCD146 
levels between the diagnosis and the first cycle of 
sunitinib correlated with PFS. Patients with an 
increase in the sCD146 plasmatic level ≥ 120%, had a 
shorter PFS (5.7 months, n=12/36) compared to 
patients with a threshold increase < 120% (some of 
these patients had a decreased or stable plasmatic 
sCD146 level, 20.5 months, n=24/36, p = 0.0301, HR 
0.084 (CI 95% 0.023-0.297), Figure 2A and Figure S5).  
 
 
Figure 1. The amount of intra-tumor CD146 mRNA correlated with pejorative evolution of M0 patients. Kaplan–Meier analysis of DFS (A) or OS (B) 
of M0 patients. DFS and OS were calculated from patient subgroups with CD146 mRNA levels that were less or greater than the first quartile. Statistical significance 
(p value) is indicated (see Table S1). 
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Figure 2. Variations in the sCD146 plasmatic levels were indicative of PFS and OS for patients treated with sunitinib. (A and B) Kaplan–Meier 
analysis of PFS: the PFS was calculated from patient subgroups with a ratio of plasmatic levels for sCD146 obtained between diagnosis and after the first cycle, which 
was less or greater than a cut-off ratio of 120%, for SUVEGIL and TORAVA trial – sunitinib group (A) or for an independent cohort of patients treated in a 
neoadjuvant setting (B). (C) Kaplan–Meier analysis of OS: OS was calculated from patient subgroups with a ratio of plasmatic levels for sCD146 obtained between 
diagnosis and after the first cycle, which was less or greater than a cut-off ratio of 120%, for SUVEGIL and TORAVA trial – sunitinib group. Statistical significance (p 
value) and the time of PFS and OS are indicated (see Figure S4 and Table S2). 
 
To confirm these results, we analyzed sCD146 in 
the plasma of ccRCC patients treated with sunitinib in 
a neo-adjuvant setting (PREINSUT clinical trial). In 
this independent cohort, patients with an increase in 
sCD146 plasmatic levels > 120%, had a shorter PFS 
(2.3 months, n=4/13) compared to patients with a 
threshold increase < 120% (24.8 months, n=9/13, p = 
0.0437, HR 0.1023 (CI 95% 0.0155-0.6727), Figure 2B). 
The variations in the sCD146 levels (inferior or 
superior to 120%) and clinical parameters of patients 
(Fuhrman grade, pT, pM or MSKCC score, the 
standard score used for patient evaluation in clinical 
practices) did not correlate (Table S2A). The biological 
and clinical parameters were then analyzed in a 
multivariate Cox regression model for PFS. Variations 
in the sCD146 levels were identified as an 
independent prognostic parameter for PFS (p = 0.001, 
HR 8.298 (CI 95% 2.221 – 31); Table S2B). Therefore, 
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the difference in sCD146 levels between the diagnosis 
and the first cycle of sunitinib can be considered as an 
independent marker for PFS. 
By using the same threshold, we then analyzed 
the correlation between variations in sCD146 levels at 
diagnosis and after the first cycle of sunitinib to OS. 
The median OS of patients with sCD146 < 120% 
included in the prospective cohort was not reached 
(NR, n=24/36) whereas patients with sCD146 ≥ 120% 
had a median OS of 11 months (n=12/36, p = 0.0452, 
Figure 2C).  
Correlation between sCD146 plasmatic levels 
and PFS and OS in the bevacizumab-based 
therapy group  
To determine the predictive role of sCD146 for 
sunitinib efficacy, we tested the modulation of 
sCD146 levels between the diagnosis and the first 
cycle of treatment in a subset of patients of the 
TORAVA clinical trial that were treated with 
bevacizumab plus IFN or temsirolimus. Their median 
PFS was 10.6 months and their median OS was 24.1 
months (Figures S4C and D). By using spline curves 
as mentioned in the Materials and Methods section, 
no specific cut-off defined populations that relapsed 
or did not relapse on bevacizumab. Therefore, the 
cut-off used for sunitinib was chosen for homogeneity 
of the results.  
The difference in median PFS of patients with 
sCD146 < 120% (10.7 months, n=25/34) and of 
patients with sCD146 ≥ 120% (10.5 months, n=9/34) 
was not significant (p = 0.6467, Figure 3A). An 
equivalent trend was obtained for OS (24.4 months for 
patients with sCD146 < 120% and 24.1 months for 
patients with sCD146 ≥ 120%, p = 0.3525, Figure 3B). 
These results strongly suggest that the 120% increase 
in the sCD146 level is predictive of sunitinib- but not 
of bevacizumab-based therapy efficacy.  
 
 
Figure 3. Variation in the sCD146 plasmatic levels did not correlate with the PFS and OS of patients treated with bevacizumab. Kaplan–Meier 
analysis of PFS (A) or OS (B) of patients with ccRCC. The PFS and OS were calculated from patient subgroups with a ratio of plasmatic levels for sCD146 obtained 
between the diagnosis and after the first cycle, which was less or greater than a cut-off ratio of 120%, for TORAVA trial – bevacizumab group. Statistical significance 
(p value) and the time of PFS and OS are indicated (see Figure S4). 
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Figure 4. Sunitinib stimulated CD146 expression in patients treated with sunitinib in a neoadjuvant setting. Tumors from untreated ccRCC patients 
and tumors from patients treated with sunitinib in a neoadjuvant setting were compared (see Table S3). The levels of CD146 total (short + long form, A), CD146 long 
(B), CD146 short (C) and angiomotin (D) mRNA were determined by qPCR. 
 
Sunitinib stimulated CD146 mRNA expression 
in ccRCC patients  
To establish a correlation between sunitinib 
treatment and CD146, we compared CD146 and 
angiomotin mRNA levels in tumors from untreated 
patients and in tumors from patients that received 
sunitinib in a neoadjuvant setting. Although tumor 
samples were not paired before and after sunitinib 
treatment, this method represents a first approach to 
understand the relationship between sCD146 and 
survival (Figure 4). These samples were independent 
of those of the PREINSUT trial for which only blood 
samples were available. These new tumor samples 
were already analyzed for another parameter [24]. In 
these tumor samples, mRNA of total CD146 (Figure 
4A) and the long (Figure 4B) and short (Figure 4C) 
CD146 isoforms were significantly increased in 
sunitinib-treated patients. No modification in 
angiomotin mRNA expression was observed between 
the two groups (Figure 4D). 
Sunitinib stimulated CD146/sCD146 
expression in sunitinib-resistant ccRCC cells 
We hypothesized that the increase in CD146 
levels, responsible for the resistance to sunitinib, 
resulted from a direct effect on tumor cells. Therefore, 
we used ccRCC cells that are respectively sensitive 
(786) and resistant (786R) to sunitinib. According to 
previous results, sunitinib resistance is dependent on 
lysosomal trapping [26]. Therefore, the resistance may 
be transient in part. Hence, 786R cells were left 
sunitinib-free for three days then re-challenged with 
different concentrations of the drug. Whereas 
sunitinib had no effect on the expression of total 
CD146, long and short forms in 786 cells, it further 
stimulated CD146 expression at the mRNA (Figures 
5A to C) and protein levels (Figure S6A-C) in 786R 
cells. In addition, it also stimulated soluble CD146 
secretion, as observed by ELISA (Figure 5D) or 
western-blot (Figure S6D) in cell culture supernatants. 
Moreover, the increase of CD146 level in 786R in basal 
conditions relies on activation of the c-Jun N-terminal 
Kinase (JNK) pathway (Figure S7). Indeed, inhibition 
of JNK by SP600125 (Figure S7A) decreased CD146 
expression at the mRNA (Figure S7B-D) and protein 
levels (membrane CD146 analyzed by FACS (Figure 
S7E), sCD146 analyzed by ELISA (Figure S7F)). These 
results strongly suggest that the CD146 produced by 
tumor cells is directly involved in resistance to 
sunitinib. They also mimic the increment of sCD146 
that we observed in relapsed patients. The basal levels 
of angiomotin mRNA were not different in 786 and 
786R cells but were increased in 786R cells stimulated 
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with a high sunitinib concentration, suggesting that 
an autocrine amplification loop on tumor cells may 
occur in resistant patients (Figure 5E). An increase in 
soluble CD146 did not occur when 786R cells were 
treated with bevacizumab (Figure S8A) and cell 
viability was not modified (Figure S8B). In addition, 
when HUVEC were treated with sunitinib, at two 
concentrations that reduced by 30% cell proliferation, 
or by bevacizumab, CD146, sCD146 and angiomotin 
were not modified (Figures S9A-D). 
 
 
Figure 5. Basal CD146 expression is higher in 786R cells and is further stimulated by sunitinib. (A to E) 786 and 786R cells were treated with 2.5 or 5 
µM sunitinib for 48 h. The mRNA levels of CD146 total (A), long (B) and short forms (C) and angiomotin (E) were evaluated by qPCR. Results are represented as 
the mean of three independent experiments ± SEM. (D) The sCD146 protein in cell supernatants was evaluated by ELISA. (F) 786 cells were treated with sunitinib, 
in the presence of recombinant sCD146 for 48 h. Cell viability was measured with a XTT assay. Results are represented as the mean of three independent 
experiments ± SEM. (G) 786 and 786R cells were treated with sunitinib (5 µM), in the presence of 1 µg/mL of irrelevant (CT Ab) or anti-sCD146 (sCD146 Ab) 
antibodies for 48 h. Cell viability was measured by XTT assays. Results are represented as the mean of three independent experiments ± SEM. * p<0.05, ** p<0.01, 
*** p<0.001. 
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The link between expression of CD146 mRNA 
and production of sCD146 following sunitinib was 
confirmed on primary cells resistant to sunitinib. 
Their IC50 for the drug is 10 µM (equivalent to the 
IC50 of 786R cells; Figure S10A). Their mRNA (total, 
long, short forms, Figure S10B-D) and protein 
(membrane CD146 analyzed by FACS (Figure S10E), 
sCD146 analyzed by ELISA (Figure S10F)) levels are 
expressed to a higher extent as compared to control 
786 cells and are further stimulated by sunitinib.  
To analyze the effect of an autocrine loop 
involving CD146 and angiomotin on sunitinib 
resistance, we then analyzed the effect of sCD146 (50 
and 100 ng/mL) on the viability of 786 cells treated 
with sunitinib (2.5 or 5 µM). sCD146 increased cell 
viability in a dose-dependent manner in 786 cells. 
Moreover, it also reduced the sunitinib-dependent 
decreased cell viability (Figure 5F). sCD146 also 
prevented the sunitinib-dependent decreased cell 
viability in another ccRCC cell line (RCC10, Figure 
S8C). sCD146 stimulated the proliferation of HUVEC 
but did not protect HUVEC from sunitinib (Figure 
S9E). 
In view of the large increase in sCD146 secretion 
in 786-R cells, we tested the effect of the anti-sCD146 
antibody, M2J-1 mAb, on cell viability. Anti-sCD146 
antibody decreased 786R but not 786 viability (Figure 
5G). This result was confirmed in proliferation 
experiments. 786-R cell proliferation was significantly 
decreased by M2J-1 mAb whereas no effect of the 
control IgG was observed (Figure S11). Altogether, 
these results strongly suggest the involvement of 
CD146 in ccRCC cell resistance to sunitinib. 
Discussion 
No curative treatment exists for metastatic 
ccRCC. Therefore, despite new therapeutic options, it 
remains a disease with poor prognosis. Two types of 
patients are currently diagnosed: i) M0 patients that 
have good prognosis although some patients progress 
toward a M1 phase without any robust method to 
predict such a pejorative evolution, and ii) M1 
patients that are treated with sunitinib in the first-line. 
The efficacy in tumor control varies from a few days 
to several years [30]. Unfortunately, relapse is 
synonymous with ineluctable death. However, ccRCC 
is probably the only disease that has led to the 
development of more than ten treatments in the last 
years. Therefore, the identification of predictive 
marker(s) of M0/M1 evolution and of sunitinib 
efficacy may allow a more accurate survey of at risk 
patients and a rapid switch to a second-line treatment 
before the detection of relapse by imaging using, for 
example, CT scans. Such markers must be detectable: 
i) with material sampled from patients by a 
non-invasive technique (urine, blood), or ii) by a 
simple and sensitive method easily transposable to 
clinical practices. The presence of high amounts of 
mRNA in tumors of patients that relapsed toward a 
M1 phenotype must be confirmed in plasma of M0 
patients. An increase in plasmatic sCD146 ≥ 120% 
between the diagnosis of a metastatic disease and the 
first cycle of sunitinib may represent such a relevant 
marker of relapse. This simple detection predicts a 
pejorative evolution that may occur after several 
cycles of treatment. This detection may highlight a 
relapse earlier than those detected by CT scans that 
are generally performed after the second cycle of 
sunitinib. 
sCD146 is generated by the shedding of the 
membrane form of CD146 through an unidentified 
process that might involve matrix metalloproteases 
[31]. CD146 is expressed on endothelial and several 
cancer cells including ccRCC cells. We observed a 
large increase in the long and short forms of the 
CD146 mRNA in tumors, which may be related to 
up-regulation on tumor and/or tumor-associated 
endothelial cells. The role of both isoforms in cancer 
cells is unknown. However, the long CD146 isoform is 
essentially involved in structural functions at the 
cell-cell junction, whereas the short CD146 isoform is 
involved in angiogenic functions in endothelial cells. 
Further studies will be necessary to delineate the roles 
of these forms in ccRCC cells. To discriminate 
between the effects on cancer and endothelial cells, we 
performed in vitro experiments with HUVEC and 786 
and 786R cells. Whereas no effect of sunitinib was 
observed on CD146 mRNA expression in HUVEC and 
a trend of decreased expression in 786 cells, a huge 
increase of total, long and short forms was observed 
in 786R cells. This effect on mRNA was associated 
with an increase in sCD146 production and in cell 
viability of 786R cells. These results were also 
consistent with increased plasmatic levels above the 
threshold of 120% observed in patients that relapsed 
on sunitinib. Thus, these experiments strongly 
suggest that one of the mechanisms of resistance to 
sunitinib may depend on a huge increase in 
CD146/sCD146 expression. sCD146 stimulates VEGF 
production leading to enhanced proliferation and 
survival of cancer cells expressing CD146 [18]. Indeed, 
sCD146 regulates numerous proteins involved in cell 
survival, cell cycle, cellular stress and nuclear proteins 
acting as transcription factors such as BCL-XL and the 
oncoprotein c-MYC, which is phosphorylated in 
response to sCD146 [18]. Finally, CD146 is involved in 
epithelial-mesenchymal transition (EMT) [32, 33]. 
Since this phenomenon plays a major role in 
metastatic dissemination, we hypothesize that 
increased CD146 expression induced by sunitinib 
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stimulates EMT and consequently accelerates 
metastatic development at relapse. A recapitulative 
schema is shown is Figure S12. In addition to its role 
as a predictive marker of relapse on sunitinib, sCD146 
may also serve as a therapeutic target. For this 
purpose, we recently developed a neutralizing 
antibody that specifically binds and inhibits the 
effects of sCD146 [18]. This antibody displayed 
inhibitory effects on two models of xenografts in nude 
mice. Indeed, the antibody reduced tumor growth 
and angiogenesis. Further experiments are ongoing to 
test the beneficial role of the sCD146 antibody at 
progression on sunitinib in experimental models of 
ccRCC.  
Conclusion 
Our study defines sCD146 as a relevant 
predictive marker of pejorative evolution of M0 
patients and of response to sunitinib in metastatic 
ccRCC. We established that an increase ≥ 120% of 
sCD146 in patients after sunitinib is indicative of a 
high risk of relapse. These results must be confirmed 
with a larger number of patients. The measurement of 
sCD146 could then be introduced into clinical pract-
ices. It would then be used to monitor the M0 patients 
and to propose alternative treatments to sunitinib in 
patients with a high risk of relapse according to 
CD146 level. In addition, our study suggests 
combining sunitinib with a CD146/sCD146-directed 
antibody or using it upon relapse on sunitinib is a 
relevant therapeutic approach. This strategy deserves 
testing in phase I/II clinical trials. 
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